About Tethys Bioscience
Tethys Bioscience is engaged in efforts to create and commercialize blood tests that accurately assess imminent disease risk with an aim of helping physicians preempt the onset of chronic cardiometabolic conditions by focusing healthcare resources on those patients who will benefit the most from early and aggressive intervention. Tethys Bioscience was established in 2005 with initial attention to type 2 diabetes, pursuing the development of an approach designed to transform the way diabetes and other cardiometabolic diseases are assessed and treated. In June 2008, Tethys unveiled its first product, the PreDx Diabetes Risk Score (PreDx DRS). PreDx DRS is a fasting blood test that combines multiple blood-borne markers and a proprietary algorithm to deliver risk stratification for patients at risk for type 2 diabetes. Tethys markets PreDx DRS directly to primary care physicians with the aim of enabling these physicians to focus interventions on their highest-risk patients so they can disrupt disease progression and preempt disease onset. Per the company, the Tethys development pipeline includes products to determine risk for first-time heart attack, osteoporotic fracture and other cardiometabolic diseases, and is also working on tests that can be used to determine the quality of diet and exercise programs.
Tethys Bioscience Patents
Tethys Bioscience has filed 6 patents.
Diabetes, Biomarkers, Transcription factors, MicroRNA, Insulin therapies
Diabetes, Biomarkers, Transcription factors, MicroRNA, Insulin therapies
Latest Tethys Bioscience News
Nov 27, 2016
Tethys Bioscience, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 17:46 EST 27 Nov 2016 | BioPortfolio Reports Home » Topics » Biotechnology Business » Latest News » Tethys Bioscience, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report Prices from USD $350 Summary MarketLine's Company Mergers Acquisitions MA, Partnerships Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Tethys Bioscience , Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes business description, detailed reports on mergers and acquisitions MA, divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Tethys Bioscience, Inc. since January 2007. Key Findings Provides intelligence on Tethys Bioscience, Inc.'s MA, strategic partnerships and alliances, capital raising and private equity transactions. Detailed reports of various financial transactions undertaken by Tethys Bioscience, Inc. and its subsidiaries since 2007. Information about key financial and legal advisors for Tethys Bioscience, Inc.'s financial deals transactions. Financial deals tables and charts covering deal value and volumes trend, deal types and geographybased deal activity. ReasonsToBuy Access comprehensive financial deals data along with charts and graph covering MA, private equity, and partnerships and alliances. Form an independent opinion about Tethys Bioscience, Inc.'s growth strategies through the organic and inorganic activities undertaken since 2007. Track your competitors' business structure and growth strategies. Related Biotechnology, Pharmaceutical and Healthcare News
Tethys Bioscience Frequently Asked Questions (FAQ)
When was Tethys Bioscience founded?
Tethys Bioscience was founded in 2002.
Where is Tethys Bioscience's headquarters?
Tethys Bioscience's headquarters is located at 5858 Horton Street, Emeryville.
What is Tethys Bioscience's latest funding round?
Tethys Bioscience's latest funding round is Dead.
How much did Tethys Bioscience raise?
Tethys Bioscience raised a total of $63.4M.
Who are the investors of Tethys Bioscience?
Investors of Tethys Bioscience include Silicon Valley Bank, Oxford Finance, Kleiner Perkins Caufield & Byers, Intel Capital, Aeris Capital and 7 more.
Who are Tethys Bioscience's competitors?
Competitors of Tethys Bioscience include Theranos and 1 more.
Compare Tethys Bioscience to Competitors
Ischemia Care is a diagnostics company in the healthcare sector, focusing on the development and commercialization of a stroke blood testing platform. The company's main service is providing highly accurate diagnosis guidance to clinicians through blood tests, which aids in the rapid treatment of complex and chronic patients. These services primarily cater to the healthcare industry. It was founded in 2009 and is based in Oxford, Ohio.
Canary Foundation was founded in 2004 by Don Listwin, a successful high-technology executive who lost his mother to misdiagnosed ovarian cancer. Don discovered that although almost $10 billion is spent annually on cancer research in the United States, the vast majority is allocated to developing new cancer treatments and caring for patients. Surprisingly, little funding is available to researchers investigating new ways to detect cancer it at its earliest, curable stages. Don made a commitment to use his time, energy, expertise, enthusiasm, professional network, and his own family foundation's resources to build a non-profit organization that will succeed at the creation of an early warning system for cancer. His ongoing passion is to build the foundation that connects the very best cancer researchers with entrepreneurs and venture capitalists so that their breakthroughs will have chances of saving lives. Don recruited Dr.Lee Hartwell, 2001 Nobel Laureate, to help form the Canary Science Team from the most outstanding, scientifically researchers available from various disciplines. Science team members come from widely different fields and institutions to meet on a regular basis where they share ideas and breakthroughs. Canary has devised a simple process to provide money and tools for team members to accomplish their stated goals at a rapid pace and with directly applicable results. Tools include software to share data, dedicated websites, project management support, quarterly collaboration meetings and project reviews. One of a decisions the Science Team made was to choose ovarian cancer as a prototype for creating an early detection blood test to detect trace amounts of proteins called biomarkers produced by cancer. Ovarian cancer was chosen as it is generally considered asymptomatic until late stage and has relatively low occurrence. Knowledge, techniques, and data gathered from the Ovarian Cancer Program are being leveraged to expand into other types of cancers (Pancreatic, Prostate and Lung). In addition to blood tests, the Science Team is working on advancing imaging techniques and agents for general body scanning technology using PET, Ultrasound and other imaging modalities for pinpointing the exact cancer location in order to eradicate it while it is still small and before it has spread. Canary hopes that by delivering on a effective test for early detection of cancer it will spur a dramatic increase of funds into the early detection field from the National Cancer Institute and the venture capital community so that products based on this research will arrive faster and save millions of lives per year.
Nodality is focused on developing highly predictive tests to enable biologically-informed clinical treatment decisions in patients with cancer and autoimmune disease.
Banyan Biomarkers is a company focused on the discovery, validation, and commercialization of biochemical markers in the healthcare sector. The company's main service is the development of a blood test that aids in the evaluation of concussions, potentially eliminating the need for CT scans in patients with suspected mild traumatic brain injury. The company primarily serves the healthcare industry, particularly in the area of traumatic brain injury diagnosis. It was founded in 2013 and is based in San Diego, California.
XEPTAGEN SpA is engaged in the discovery and validation of molecular markers in order to produce diagnostic kits for the early detection, monitoring, and screening of cancerous cells. By exploiting the natural immune response to early stage cancer and the platform technology Combinatorial Proteomic, XEPTAGEN has discovered specific tumor markers that lead to an earlier and much more accurate detection of developing carcinomas. The company's mission includes creating tools that improve the diagnostic accuracy for cancer and the clinical management of cancer patients.
Integrative Diagnostics is a early cancer detection company founded by Leroy Hood.